Infugem patents expiration

INFUGEM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948 SUN PHARM Ready to be infused gemcetabine solution
Jul, 2033

(9 years from now)

Infugem is owned by Sun Pharm.

Infugem contains Gemcitabine Hydrochloride.

Infugem has a total of 1 drug patent out of which 0 drug patents have expired.

Infugem was authorised for market use on 16 July, 2018.

Infugem is available in solution;intravenous dosage forms.

The generics of Infugem are possible to be released after 01 July, 2033.

Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 July, 2018

Treatment: NA


More Information on Dosage

INFUGEM family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic